NCT01119118 2019-11-21
ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer
University of Wisconsin, Madison
Phase 2 Terminated
Clinical Trials
13 trialsNCT01134497 2018-05-22
PLANET
Cardiff University
Phase 2 Withdrawn
NCT00554229 2016-02-08
ENTHUSE M1
AstraZeneca
Phase 3 Completed
NCT01205711 2014-07-08
FOLFERA
Cardiff University
Phase 2 Completed
NCT01000948 2014-01-08
DAPROCA-1
Aarhus University Hospital
Phase 2 Terminated
NCT00314782 2013-03-12
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
AstraZeneca
Phase 1 Completed
NCT00090363 2013-01-08
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
AstraZeneca
Phase 2 Completed
NCT00055471 2012-10-31
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
AstraZeneca
Phase 2 Completed
NCT00617669 2012-09-10
ENTHUSE M1C
AstraZeneca
Phase 3 Completed
NCT00626548 2012-09-03
ENTHUSE M0
AstraZeneca
Phase 3 Terminated
NCT00929162 2012-08-07
ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
AstraZeneca
Phase 2 Terminated
NCT00745875 2012-06-06
ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
AstraZeneca
Phase 2 Completed
NCT00997945 2011-05-19
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed